Prostatype Genomics AB (DE:PGO0)
FRANKFURT:PGO0
PGO0 Stock Chart & Stats
€0.05
-€0.02(-2.92%)
At close: 4:00 PM EST
€0.05
-€0.02(-2.92%)
Day’s Range― - ―
52-Week Range€0.01 - €0.14
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.93M
Enterprise Value€6.11M
Total Cash (Recent Filing)€12.93M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.49
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.20
Shares Outstanding59,189,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€113.90K
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt in 2025 materially reduces near-term solvency risk and interest burden, giving management flexibility to pursue commercialization or partner deals. This durable balance sheet characteristic lowers forced liquidity pressures over the next several months.
Specialized Diagnostic PlatformA narrow focus on a clinically oriented prognostic test builds expertise, data continuity and a clearer regulatory/commercial path. This specialization supports durable clinical adoption potential and differentiation versus broader diagnostic players over a multi-month horizon.
Per-test Revenue Model & Distribution ChannelsA per-test billing model tied to clinical use creates recurring, volume-linked revenue potential as adoption grows. Distribution and lab partnership channels provide scalable routes to expand test volumes without proportional fixed-cost increases, supporting sustainable topline expansion if uptake improves.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow forces reliance on external financing or equity issuance, which can dilute shareholders and limit strategic options. Even with burn reduced in 2025, ongoing negative cash generation is a structural constraint on scaling commercialization efforts.
Deep, Sustained LossesWide negative margins and repeated operating losses indicate the current cost structure is far above revenue run-rate, limiting ability to self-fund growth. Until fixed costs are absorbed by materially higher test volumes or margins improve, losses will pressure equity and investment in commercialization.
Small, Volatile Revenue BaseA low and inconsistent revenue base reduces predictability and undermines economies of scale needed for diagnostics. The recent year-over-year decline signals fragile commercial traction, making multi-month forecasts and investment decisions riskier absent evidence of stable demand growth.
PGO0 FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was €0.01 and its highest was €0.14 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is €2.93M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 31, 2026 which is in 83 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -€0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.036.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 59,189,320 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -€0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.899%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in DE:PGO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.